About Progenity
Progenity is a company based in San Diego (United States) founded in 2011 by Harry Stylli. Progenity has raised $216.63 million across 9 funding rounds from investors including Athyrium Capital Management. The company has 125 employees as of December 31, 2022. Progenity has completed 1 acquisition, including Carmenta Bio. Progenity offers products and services including BioJet and NaviCap. Progenity operates in a competitive market with competitors including Natera, BillionToOne, SYNLAB, Beikang Medical and Yourgene Health, among others.
- Headquarter San Diego, United States
- Employees 125 as on 31 Dec, 2022
- Founders Harry Stylli
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biora Therapeutics, Inc.
-
Annual Revenue
$1.25 M (USD)670as on Dec 31, 2021
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$216.63 M (USD)
in 9 rounds
-
Latest Funding Round
$40 M (USD), Post-IPO
May 11, 2021
- Investors
-
Employee Count
125
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Progenity
Progenity offers a comprehensive portfolio of products and services, including BioJet and NaviCap.
Provides needle-free oral delivery of large molecules for chronic diseases.
Enables targeted oral delivery of therapeutics in specific body areas.
People of Progenity
Unlock access to complete
Unlock access to complete
Funding Insights of Progenity
Progenity has successfully raised a total of $216.63M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Progenity
Progenity has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Progenity
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Progenity
Progenity has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Carmenta Bio.
Investment portfolio details for Progenity
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnostics for women's health
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for Progenity
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Progenity
Detailed financials for Progenity
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Progenity Comparisons
Peer comparison for Progenity
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Progenity
Progenity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, BillionToOne, SYNLAB, Beikang Medical and Yourgene Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Provider of medical diagnosis and clinical laboratory analysis services
|
|
| Locked | Locked | Locked |
NGS-based diagnostic solutions for neonatal screening are developed.
|
|
| Locked | Locked | Locked |
Non-invasive prenatal genetic tests and genomic services are provided.
|
Detailed competitors of Progenity
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Progenity
Complete news archive for Progenity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Progenity
Progenity was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Progenity is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Harry Stylli is the current CEO of Progenity. They have also founded this company.
Progenity is a funded company, having raised a total of $216.63M across 9 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Progenity is 125.
Annual revenue of Progenity is $1.25M as on Dec 31, 2021.
Provider of non-invasive prenatal genomic testing. The companys diagnostic platform is based on genomics, epigenomics, proteomics, and metabolomics. The companys products include a Preparent carrier test for prenatal genetic disorders, an Innatal prenatal screen for chromosomal-related disorders, hereditary cancer risk prediction, and Resura prenatal test for detecting monogenic disorders. The company also developing precision medicine for prenatal, perinatal, oncology, and gastroenterology diseases.
Progenity's top competitors include Natera, BillionToOne and Pictor.
Progenity offers BioJet and NaviCap.
Progenity has made 1 acquisition, including Carmenta Bio.
Progenity has 1 investor. Key investors include Athyrium Capital Management.